Polytherapeutic strategies with oncolytic virus–bortezomib and adjuvant NK cells in cancer treatment

Proteasome inhibition and oncolytic virotherapy are two emerging targeted cancer therapies. Bortezomib, a proteasome inhibitor, disrupts the degradation of proteins in the cell leading to accumulation of unfolded proteins inducing apoptosis. On the other hand, oncolytic virotherapy uses genetically...

Descripción completa

Detalles Bibliográficos
Autores principales: Aspirin, Angelica P., de los Reyes V, Aurelio A., Kim, Yangjin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society 2021
Materias:
Life Sciences–Mathematics interface
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879760/
https://www.ncbi.nlm.nih.gov/pubmed/33402021
http://dx.doi.org/10.1098/rsif.2020.0669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879760/
https://www.ncbi.nlm.nih.gov/pubmed/33402021
http://dx.doi.org/10.1098/rsif.2020.0669

Ejemplares similares